ERBB2 and neoplasm: Zenocotuzumab (MCLA-128) is a novel bispecific IgG1 anti-HER2 Ab targeting HER2 and HER3 receptors under enhanced ADCC, thereby blocking HER2-HER3 heterodimerization and down-signaling the neuregulin/HER3 tumour-signalling pathway [88].